ArticleJournal of cardiothoracic surgery2026
A rare case of giant cardiac malignant tumor with positive panel reactive antibody.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA 31-year-old female patient presented with a giant primary cardiac malignancy occupying the right atrium and invading the tricuspid valve and right ventricle.
methodsDue to the inoperability of the tumor by conventional surgery, heart transplantation was considered. However, the patient had a strongly positive panel reactive antibody (PRA), indicating a high risk of rejection. Our team performed an emergency heart transplantation and administered a combination of immunosuppressive therapies postoperatively.
resultOne month after the transplantation, the patient recovered smoothly and was discharged from the hospital.
conclusionDespite giant cardiac sarcoma and high PRA-mediated rejection risk, tailored perioperative strategies, including aggressive desensitization, multimodal immunosuppression, and close surveillance, enabled successful transplantation and recovery. This highlights the feasibility of heart transplantation in select sarcoma cases with meticulous rejection management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.